|
 |
 |
Home > What's New > Lilly Off-Label Marketing Settlement Results in $750,000 to 340B Entities |
 |
 |
|
|
|
Lilly Off-Label Marketing Settlement Results in $750,000 to 340B Entities
The U.S. Department of Justice announced a civil settlement agreement with Eli Lilly January 15th to settle allegations that it caused invalid claims for payment for the anti-psychotic drug Zyprexa to be submitted to various government programs. As part of the settlement, Lilly agreed to send refunds of over $750,000 to affected 340B covered entities . Within 60 days of the date in which the court accepts the Eli Lilly’s guilty plea in connection with the Federal Criminal Action and imposes the agreed-upon sentence, Eli Lilly has agreed to mail to each affected Public Health Service entity a check in the amount of its proportionate share along with a cover letter referencing the Settlement Agreement. By cashing the check, the entity is releasing Eli Lilly from liability.
Department of Justice Press Release
Settlement
Agreement
Additional Information from DOJ
|
|
|
|
|
Washington, DC 20005 
